Cargando…

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients

BACKGROUND: Healthcare-associated infections involving Gram-negative bacteria (GNB) with difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered outcomes and poses daily therapeutic challenges in most of intensive care units worldwide. Over the recent years, four...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbier, François, Hraiech, Sami, Kernéis, Solen, Veluppillai, Nathanaël, Pajot, Olivier, Poissy, Julien, Roux, Damien, Zahar, Jean-Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354316/ https://www.ncbi.nlm.nih.gov/pubmed/37462830 http://dx.doi.org/10.1186/s13613-023-01153-6

Ejemplares similares

Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics
por: Zmarlicka, Monika T, et al.
Publicado: (2015)

New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
por: Nurjadi, Dennis, et al.
Publicado: (2022)

716 Risk Factors for Resistance to Beta-lactam/Beta-lactamase Inhibitors and Carbapenems in Bacteroides spp. Bacteremia
por: Smith, Janessa, et al.
Publicado: (2014)

Dual beta-lactam treatment: Pros and cons
por: Guerra, Diogo, et al.
Publicado: (2022)

The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2022)

162. Assessment of Beta-lactam Allergies as Rationale for Receipt of Vancomycin for Surgical Prophylaxis
por: Tucker, Kendall J, et al.
Publicado: (2020)

Beta lactam hypersensitivities
por: Azoury, Marie Eliane*, et al.
Publicado: (2014)

Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs
por: Connelly, Sheila, et al.
Publicado: (2019)

Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor
por: Russ, Dor, et al.
Publicado: (2020)

Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Beta-lactam allergy labeling in intensive care units: An observational, retrospective study
por: Leone, Marc, et al.
Publicado: (2021)

Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis
por: Cheng, Matthew P, et al.
Publicado: (2019)

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms
por: Bianco, Gabriele, et al.
Publicado: (2022)

About the usefulness of contact precautions for carriers of extended-spectrum beta-lactamase-producing Escherichia coli
por: Zahar, Jean-Ralph, et al.
Publicado: (2015)

In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa
por: Lomovskaya, Olga, et al.
Publicado: (2021)

Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: A systematic literature review and meta-analysis
por: Wilson, Geneva M., et al.
Publicado: (2021)

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
por: Shields, Ryan K, et al.
Publicado: (2023)

1297. In-Vitro Antibacterial Activities of Cefiderocol (S-649266) Alone and With the Addition of Beta-Lactamase Inhibitors Against Multidrug-resistant Acinetobacter baumannii
por: Abdul-Mutakabbir, Jacinda C, et al.
Publicado: (2020)

1805. Safety Outcomes Following Beta-Lactam use in Patients with a Documented Beta-Lactam Allergy
por: Rampersad, Daniel, et al.
Publicado: (2022)

Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy
por: Nasir, Nosheen, et al.
Publicado: (2019)

Progressive Sub-MIC Exposure of Klebsiella pneumoniae 43816 to Cephalothin Induces the Evolution of Beta-Lactam Resistance without Acquisition of Beta-Lactamase Genes
por: Anderson, Jasmine R., et al.
Publicado: (2023)

The potential role of microbiota for controlling the spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) in neonatal population
por: Delerue, Thibaud, et al.
Publicado: (2017)

Genetic associations in beta-lactam allergy
por: Gueant, Jean-Louis, et al.
Publicado: (2014)

Endopeptidase-Mediated Beta Lactam Tolerance
por: Dörr, Tobias, et al.
Publicado: (2015)

Profile of Enterobacteria Resistant to Beta-Lactams
por: Santos, Andressa Liberal, et al.
Publicado: (2020)

Evolution of β-lactamase-mediated cefiderocol resistance
por: Fröhlich, Christopher, et al.
Publicado: (2022)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

Novel Beta-Lactam/Beta-Lactamase Plus Metronidazole vs Carbapenem for Complicated Intra-abdominal Infections: A Meta-analysis of Randomized Controlled Trials
por: Che, Haoyue, et al.
Publicado: (2020)

Prevalence and Abundance of Beta-Lactam Resistance Genes in Hospital Wastewater and Enterobacterales Wastewater Isolates
por: Santosaningsih, Dewi, et al.
Publicado: (2023)

Can the use of older-generation beta-lactam antibiotics in livestock production over-select for beta-lactamases of greatest consequence for human medicine? An in vitro experimental model
por: Ogunrinu, Olanrewaju J., et al.
Publicado: (2020)

1621. Novel Beta-lactam Beta-lactamase Inhibitors Against Alternative Antibiotics for the Treatment of Complicated Urinary Tract Infections and Pyelonephritis Caused by Carbapenem-resistant Enterobacterales
por: Green, Bliss, et al.
Publicado: (2020)

Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Critically Ill Patients: Impact of Carriage And Infection On Carbapenem Consumption, Duration of Icu Stay, And Mortality
por: Barbier, F, et al.
Publicado: (2015)

THE BETA-LACTAM ANTIBIOTICS: Penicillins and Cephalosporins in Perspective
Publicado: (1980)

Beta-lactam hypersensitivity: not always what it seems
por: Andrade, Djanira, et al.
Publicado: (2015)

Use of beta-lactams antibiotics in ICU patients
por: Damas, M-P, et al.
Publicado: (2015)

Approach for delabeling beta-lactam allergy in children
por: Sáenz de Santa María, R., et al.
Publicado: (2023)

Continuous beta-lactam infusion in critically ill patients: the clinical evidence
por: Abdul-Aziz, Mohd H, et al.
Publicado: (2012)

Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases
por: Lomovskaya, Olga, et al.
Publicado: (2020)

Outcomes of Beta-Lactam Allergic and Non-Beta-Lactam Allergic Patients with Intra-Abdominal Infection: A Case–Control Study
por: Naciri, Tayma, et al.
Publicado: (2022)

Structural insight into YcbB-mediated beta-lactam resistance in Escherichia coli
por: Caveney, Nathanael A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n14rlc88d5vvorp5bs2b9sllhc